Rongene Pharma brochure en_2012.2
3
8 Dongfu Road, Suzhou Industrial Park, Suzhou, China 215123 | www.rongene.com Integrated Drug Discovery Dedicated to Novel Drug Candidates for our Customers Overview Rongene is a global pharmaceutical firm launching the innovative drug discovery platform. Our platform assists our clients with customized lead compounds and preclinical drug candidates. Our clients include pharmaceutical, biotech companies, research institutes, universities, and governmental organizations etc. Rongene also provides a comprehensive portfolio of services in early stage drug discovery and development in an efficient and cost-effective manner. Drug Discovery Platform Our creative platform focuses on target analysis, drug design, assay development, library screening, hit to lead, lead optimization, and preclinical evaluation. It is seamlessly integrated with drug information database, precise and multiple target screening, druggability, ADMET indicators, bioassay, hit evaluation, zebrafish early evaluation and animal model for further development. This platform has successfully helped our clients in drug design/discovery with decades of experiences and strong track performance record of our team. Discovery Capabilities Our platform is equipped with a wide range of proprietary technologies and state-of-the-art facilities, which consist of commercial drug design software packages, innovative modeling algorithms and databases, high performance computing system, multimode plate readers, microscopes, etc. The team members have also authored over 200 publications in top-tier journals with over 1,500 citations, and filed over 10 drug discovery patents and software copyrights. Service and Research The tailored solutions and services for each project will be provided for drug discovery to search, evaluate, optimize the novel lead compounds and define the preclinical drug candidates through our In Silico, In Vitro and In Vivo techniques. Our scientists will be working closely with the respective customers to integrate their specific expertise and, where appropriate, to draw on customized research tools, solutions and materials. Discovery research is able to provide the customized lead compounds and preclinical drug candidates based on the targets and diseases required by our clients; optimize and profile the lead structures by our defined criteria, and identify the active ingredients and mode of action for natural products based on our discovery platform. Target Analysis Target Screening Hit Evaluation Lead Optimization Preclinical Development
Transcript of Rongene Pharma brochure en_2012.2
8 Dongfu Road, Suzhou Industrial Park, Suzhou, China 215123 | www.rongene.com
Integrated Drug DiscoveryDedicated to Novel Drug Candidates for our Customers
Overview
Rongene is a global pharmaceutical firm launching the innovative drug discovery platform. Our platform assists our clients with customized lead compounds and preclinical drug candidates. Our clients include pharmaceutical, biotech companies, research institutes, universities, and governmental organizations etc. Rongene also provides a comprehensive portfolio of services in early stage drug discovery and development in an efficient and cost-effective manner.
Drug Discovery Platform
Our creative platform focuses on target analysis, drug design, assay development, library screening, hit to lead, lead optimization, and preclinical evaluation. It is seamlessly integrated with drug information database, precise and multiple target screening, druggability, ADMET indicators, bioassay, hit evaluation, zebrafish early evaluation and animal model for further development. This platform has successfully helped our clients in drug design/discovery with decades of experiences and strong track performance record of our team.
Discovery Capabilities
Our platform is equipped with a wide range of proprietary technologies and state-of-the-art facilities, which consist of commercial drug design software packages, innovative modeling algorithms and databases, high performance computing system, multimode plate readers, microscopes, etc. The team members have also authored over 200 publications in top-tier journals with over 1,500 citations, and filed over 10 drug discovery patents and software copyrights.
Service and Research
The tailored solutions and services for each project will be provided for drug discovery to search, evaluate, optimize the novel lead compounds and define the preclinical drug candidates through our In Silico, In Vitro and In Vivo techniques. Our scientists will be working closely with the respective customers to integrate their specific expertise and, where appropriate, to draw on customized research tools, solutions and materials. Discovery research is able to provide the customized lead compounds and preclinical drug candidates based on the targets and diseases required by our clients; optimize and profile the lead structures by our defined criteria, and identify the active ingredients and mode of action for natural products based on our discovery platform.
Target Analysis
Target Screening
Hit Evaluation
Lead Optimization
Preclinical Development
8 Dongfu Road, Suzhou Industrial Park, Suzhou, China 215123 | www.rongene.com
In Silico In Vitro In Vivo R & D
Virtual Screening• molecular docking• MD simulation• Free energy calculation• Pharmacophore model
Structure Optimization• QSAR analysis• Similarity search• Sca�old hopping
Library Design• Diverse library design• Focused library design• Combinatorial design
ADME/T Modeling
Assay development• Biochemical assay• Cellular assay
Library screening• Primary screening• Secondary screening• Iterative screening
Hit to lead• Cellular selectivity• Cellular pharmacology• Chemical amenability• IP assessment• Mode of action
ADME/T Pro�ling
Zebra�sh Platform• mRNA expression marker • Anti-Angiogenesis• Neurological disorder• Cardiovascular• Skeletal disease• Immunological model• Toxicity test
Animal Model• Early Tox studies• In vivo PK/PD studies*• In vivo e�cacy• Safety assessment*
* conducted with partners
Drug Discovery• Lead discovery• Preclinical drug candidate
Lead Optimization
Natural Product• Extraction analysis• Active ingredient identi�cation• Isolation, speci�cation
Target Analysis
Target Screening
Hit Evaluation
Lead Optimization
Preclinical Development
Clinical Trial
HY-004 (cerebral hemorrhage)
HY-029 (cerebral hemorrhage)
HY-001 (Anticancer)
HT-007 (Anticancer)
ML-019 (Anti-angiogenesis)
MYSL-003 (Anti-atherosclerosis)
Pipeline
Rongene discovery group has started 6 novel leads projects in oncology and cardiovascular. The team also seek the collaboration with our customers and strategic partners with the expertise and capability who are interested to acquire and develop the early-stage drug candidates from discovery through development and commercialization.
If you are interested in initiating your own early-stage drug discovery projects, and partnering in any of drug discovery programs, please contact us.
